Quantifying the burden of cardiac amyloid: The future is about numbers!

[1]  W. Jentzen,et al.  Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis , 2022, Journal of Nuclear Cardiology.

[2]  P. Elliott,et al.  Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis , 2021, EJNMMI Research.

[3]  C. Loewe,et al.  In Vivo Quantification of Myocardial Amyloid Deposits in Patients with Suspected Transthyretin-Related Amyloidosis (ATTR) , 2020, Journal of clinical medicine.

[4]  R. Falk,et al.  Absolute Quantitation of Cardiac 99mTc-Pyrophosphate Using Cadmium-Zinc-Telluride–Based SPECT/CT , 2020, The Journal of Nuclear Medicine.

[5]  Shuyang Zhang,et al.  Assessment of cardiac amyloidosis with 99mTc-pyrophosphate (PYP) quantitative SPECT , 2020, EJNMMI Physics.

[6]  E. Klotz,et al.  DPD Quantification in Cardiac Amyloidosis , 2020, JACC. Cardiovascular imaging.

[7]  P. Haaf,et al.  Quantitative 99mTc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores , 2019, Journal of Nuclear Cardiology.

[8]  Sanjiv J. Shah,et al.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization , 2019, Journal of Nuclear Cardiology.

[9]  R. Falk,et al.  Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. , 2019, JACC. Heart failure.

[10]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[11]  P. Hawkins,et al.  Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[12]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[13]  J. Goldsmith,et al.  Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. , 2016, JAMA cardiology.

[14]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[15]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[16]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[17]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[18]  DPD Quanti fi cation in Cardiac Amyloidosis A Novel Imaging Biomarker , 2022 .